The largest clinical trial ever undertaken by CSL Behring is now underway with CSL112, a novel plasma derived apolipoprotein A-1 infusion therapy that has been shown to have an immediate and significant impact on the ability to remove cholesterol from atherosclerotic arteries. CSL112 has the potential to reduce early recurrent cardiovascular events, experienced by nearly one in five survivors of acute myocardial infarction or heart attack. If successful, CSL112 will be a transformative growth driver for CSL and will help to address one of the world’s most prevalent and devastating diseases.
Type 2 diabetes is one of the fastest growing chronic diseases. We are currently investigating the potential of CSL346, a monoclonal antibody that binds VEGF-B, to decrease the progression of diabetic complications by targeting fatty acid metabolism.
Cardiovascular disease is the leading cause of death globally, and the prevalence of diabetes is reaching almost epidemic proportions. Additional novel therapeutic opportunities are being explored and sought for the treatment of these serious diseases impacting global health.